Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

Ana Triguero1 · Alexandra Pedraza1 · Manuel Pérez-Encinas2 · María Isabel Mata-Vázquez3 · Patricía Vélez4 · Laura Fox5 · Montse Gómez-Calafat6 · Regina García-Delgado7 · Mercedes Gasior8 · Francisca Ferrer-Marín9 · Valentín García-Gutiérrez10 · Anna Angona11 · María Teresa Gómez-Casares12 · Beatriz Cuevas13 · Clara Martínez14 · Raúl Pérez15 · José María Raya16 · Lucia Guerrero17 · Ilda Murillo18 · Beatriz Bellosillo4 · Juan Carlos Hernández-Boluda6 · Cristina Sanz1 · Alberto Álvarez-Larrán1 on behalf of On behalf of the MPN Spanish Group (GEMFIN)

Received: 3 July 2022 / Accepted: 17 August 2022 / Published online: 30 August 2022 © The Author(s) 2022, corrected publication 2022

Abstract
Hematological control, incidence of complications, and need for cytoreduction were studied in 453 patients with low-risk polycythemia vera (PV) treated with phlebotomies alone. Median hematocrit value decreased from 54% at diagnosis to 45% at 12 months, and adequate hematocrit control over time (<45%) was observed in 36%, 44%, and 32% of the patients at 6, 12, and 24 months, respectively. More than 5 phlebotomies per year in the maintenance phase were required in 19% of patients. Worsening thrombocytosis, age >60 years, and microvascular symptoms constituted the main indications for starting cytoreduction. Median duration without initiating cytoreduction was significantly longer in patients younger than 50 years (<0.0001). The incidence rate of thrombosis under phlebotomies alone was 0.8% per year and the estimated probability of thrombosis at 10 years was 8.5%. The probability of arterial thrombosis was significantly higher in patients with arterial hypertension whereas there was a trend to higher risk of venous thrombosis in cases with high JAK2V617F allele burden. Rates of major bleeding and second primary neoplasm were low. With a median follow-up of 9 years, survival probability at 10 years was 97%, whereas the probability of myelofibrosis at 10 and 20 years was 7% and 20%, respectively. Progression to acute myeloid leukemia was documented in 3 cases (1%). Current management of low-risk PV patients is associated with low rate of thrombosis and long survival. New treatment strategies are needed for improving hematological control and, in the long term, reducing progression to myelofibrosis.

Keywords Polycythemia vera · Low-risk · Phlebotomies · Thrombosis · Myelofibrosis

Introduction
Polycythemia vera (PV) is a myeloproliferative disorder characterized by clonal erythrocytosis and increased risk of hemorrhagic and thrombotic events [1]. Risk-adapted therapy relies on the presence of two risk factors, with low risk defined as age <60 years without thrombosis history and high risk by either the presence of age ≥60 years or thrombosis history [2]. Other factors such as leukocytosis or high JAK2V617F allele burden have been related with the risk of thrombosis and disease progression, but they are not included in risk stratification yet [3–6].

The main objective of therapy in low-risk PV is controlling symptoms and preventing thrombotic and hemorrhagic events. Standard first-line therapy for low-risk patients includes primary prophylaxis of thrombosis with low-dose aspirin and Hct control with phlebotomies. Although cytoreductive therapy might result in a higher reduction of thrombosis than phlebotomies alone, the use of hydroxyurea in low-risk PV patients is not recommended since the potential carcinogenic and teratogenic risk of this treatment could be greater than its benefit in reducing thrombosis [2, 7–12].
The recent approval of new agents, such as ropeginterferon and ruxolitinib, has changed the treatment scenario for PV [13–16]. Moreover, the potential disease-modifying effect of ropeginterferon has increased interest of this drug in low-risk patients, and new recommendations have recently been published to guide the indication for cytoreductive therapy [17]. However, the actual impact of phlebotomies in reducing thrombo-hemorrhagic complications in low-risk PV and their ability to achieve hematological and symptomatic control have not been extensively assessed.

The objective of this study was to evaluate the hemato logic control, complications, and cytoreductive needs of a large series of 453 patients with low-risk PV from the Spanish Registry of PV. These new data will help to understand the real unmet needs of these patients and to position these new drugs in the therapeutic algorithm of the disease.

**Patients and methods**

The Spanish Registry of Polycythemia Vera was initiated in July 2011 and is periodically updated. It is sponsored by GEMFIN (Grupo Español de Enfermedades Mieloproliferativas Fisaléfia Negativas). By April 2021, a total of 2245 patients from 60 Spanish hospitals were included in the registry. Patients were eligible for inclusion in the present study if they had low-risk PV and were treated only with phlebotomies. Informed consent for the inclusion in this registry and the scientific use of these data was obtained in accordance with the requirements of the local ethics committees.

A total of 453 patients with low-risk PV diagnosed according to the world Health Organization (WHO) criteria were included. Low-risk PV was defined as age < 60 years old and no history of prior thrombosis. The phlebotomy indication was made by the treating hematologist with the objective to maintain the Hct below 45% according to ELN recommendations [2]. Primary prophylaxis of thrombosis with antiplatelet therapy, usually low-dose aspirin, was indicated in all patients unless contraindicated. All patients were treated in tertiary centers with weekly visits until Htc control and every 3–4 months during the second year and thereafter.

Disease-related symptoms including pruritus, microvascular disturbances and splenomegaly, hemoglobin (Hb), Hct, leukocyte count, and platelet count were assessed at PV diagnosis and at months 6, 12, 18, 24, 36 and 60 months while undergoing phlebotomy therapy alone. Date and reason for starting cytoreductive therapy; main disease complications including thrombosis, bleeding, disease progression, and second primary neoplasia; and status at last follow-up were recorded. Thrombosis was defined according to the International Classification of Diseases (ninth revision) including superficial thrombophlebitis. Severe hemorrhage was defined as a symptomatic bleeding in a critical organ, or an overt hemorrhage requiring transfusion or associated with an Hb decrease > 20 g/l without transfusion.

Survival, disease progression, thrombosis, hemorrhage, and second primary neoplasms during phlebotomy therapy were calculated. Time to first thrombotic event was calculated from diagnosis with patients being censored at the last visit or at the time of initiating cytoreduction. Survival and time to disease progression were calculated until last contact, including follow-up after cytoreduction initiation. Time to event curves were drawn by the method of Kaplan and Meier with the log-rank test for comparisons. Multivariate analysis was performed by the Cox regression. Statistical analyses were performed with SPSS, version 25. Relative survival was estimated by the cohort method as described by Dickman from life tables of all-cause mortality in the Spanish population, stratified by age, sex, and calendar year of diagnosis, that were obtained from the Human Mortality Database. Relative survival analysis was performed with Stata, v.14 (www.stata.com). The incidence rate of the main clinical outcomes was also calculated as the number of events/total follow-up in person-years.

**Results**

**Main clinical and hematological values at diagnosis and during follow-up in low-risk PV patients managed with phlebotomies alone**

The main clinical characteristics at diagnosis of PV are shown in Table 1. The median age was 49 years, and 256 patients (57%) were male. In addition to phlebotomies, concomitant antiplatelet therapy was used in 90% of patients. Microvascular symptoms were present in 172 patients (39%) at diagnosis, including erythromelalgia, headache, visual alterations, and paresthesia in 8%, 25%, 3%, and 8% of the patients, respectively.

Persistence of microvascular symptoms under phlebotomy treatment was reported in 12%, 13%, 10%, 7%, and 13% of the patients at 12, 24, 36, 48, and 60 months of therapy, respectively. As for pruritus, it was present in 147 patients (33%) at diagnosis and persisted in 20%, 20%, 16%, 19%, and 25% of the patients at 12, 24, 36, 48, and 60 months of phlebotomy treatment, respectively. Spleen remained palpable in 2%, 5%, 8%, 7%, and 5% of the patients at months 12, 24, 36, 48, and 60, respectively, being symptomatic in half of them.

Hemoglobin values and hematocrit levels over time are shown in Fig. 1. As can be seen, the median Hct value decreased from 54% at baseline to 46.7% and 45% in the assessments corresponding to 6 and 12 months, respectively.
The percentage of patients with adequate hematocrit control over time (< 45%) was 36%, 44%, 36%, and 32% at 6, 12, 18, and 24 months after diagnosis, respectively. These figures decreased to 29%, 30%, and 30% at 3, 4, and 5 years, respectively.

Conventional phlebotomy was the most frequent procedure, while erythroapheresis was used in 8.5% of patients. Median whole blood volume extracted in each procedure was 450 ml for conventional phlebotomy and 440 ml of red blood cell concentrate for erythroapheresis. Complete data on the number of phlebotomy/erythroapheresis procedures during the entire observation period were available in 109 cases; the median number of phlebotomies was 6 (range: 2–26) in the first year of therapy and 3 phlebotomies per year (range: 1–11) during the second year and thereafter. More than 5 phlebotomies per year in the maintenance phase (after first year of therapy) were required in 19% of patients.

Leukocytosis > 15 × 10^9/l was present in 34 (7.5%) patients at diagnosis. Leukocyte counts over time are showed in Fig. 2. Median leukocyte counts remain stable under phlebotomies with leukocytosis > 15 × 10^9/l being reported in 11%, 11%, 15%, 13%, and 11% of the patients at months 12, 24, 36, 48, and 60, respectively. Platelet counts are shown in Fig. 2. As can be seen, median platelet count increased after starting phlebotomies with thrombocytosis > 1000 × 10^9/l being reported 2.4% at diagnosis and in 4%, 2.5%, 4%, 6%, and 7% of the patients at months 12, 24, 36, 48, and 60, respectively. Extreme thrombocytosis (platelet count > 1500 × 10^9/l) was not reported in any case at diagnosis or during follow-up.

### Table 1 Main clinical characteristics at diagnosis in 453 low-risk patients from the Spanish Registry of Polycythemia Vera

| Parameter                                      | Value            |
|-----------------------------------------------|------------------|
| Age, median (range)                           | 49 (16–60)       |
| < 50 years, n (%)                             | 245 (54)         |
| Male sex, n (%)                               | 256 (57)         |
| Cardiovascular risk factors, n (%)            |                  |
| Smoking                                       | 133 (29)         |
| Diabetes mellitus                             | 26 (6)           |
| Hypertension                                  | 115 (25)         |
| Hypercholesterolemia                          | 68 (15)          |
| Symptomatic burden, n (%)                     | 5 (1)            |
| Minor hemorrhage                              | 172 (39)         |
| Microvascular symptoms                        | 147 (33)         |
| Hematological values, median (IQR)            |                  |
| Hemoglobin, g/l                               | 176 (163–190)    |
| Hematocrit, %                                 | 54 (50–59)       |
| Leukocyte count × 10^9/l                      | 9.4 (7.8–12)     |
| Platelets × 10^12/l                           | 478 (335–630)    |
| Palpable spleen, n (%)                        | 65 (15)          |
| JAK2V617F mutation, n (%)                     | 386 (97)         |
| %VAF (median, extremes)                       | 52 (16–75)       |
| Exon 12, n (%)                                | 11 (3)           |

* Available in 414 of 453 patients. IQR, interquartile range; VAF, variant allele frequency

The percentage of patients with adequate hematocrit control over time (< 45%) was 36%, 44%, 36%, and 32% at 6, 12, 18, and 24 months after diagnosis, respectively. These figures decreased to 29%, 30%, and 30% at 3, 4, and 5 years, respectively.
Duration of therapy with phlebotomies alone and reasons to start cytoreduction

During follow-up, 272 out of 453 (60%) patients were initiated on cytoreductive treatment. Median time elapsed from diagnosis to cytoreduction start was 5.7 years (0.1–26). The main indications for starting cytoreduction are shown in Table 2. First-line cytoreductive treatments included hydroxyurea and interferon in 258 (57%) and 14 (3%) patients, respectively. The median duration of therapy with phlebotomy alone was significantly longer in patients younger than 50 years than in those older than 50 years (8.4 years versus 3 years, respectively, \( p < 0.0001 \)) (Fig. 3).

Survival and disease progression

With a median follow-up of 9 years, 23 (5%) patients died resulting in an estimated mean survival of 33 years (95%CI: 30–36). The survival probability at 10 and 20 years was 97% and 92%, respectively. Relative survival (RS) with the matched general population of same age and sex is shown in Fig. 4. Patients died at the same rate as that of Spanish general population with the relative survival at 20 years being 1 (Fig. 3). Causes of death included the following: disease progression \( n = 4 \), thrombosis \( n = 3 \), major bleeding \( n = 1 \), infection \( n = 4 \), second primary neoplasia \( n = 3 \), heart failure \( n = 2 \), other \( n = 2 \), not reported \( n = 2 \). Median age at time of death was 64 years (range: 25–86), with 8 patients being younger than 60 years. Only three patients were receiving phlebotomies alone (in addition to the standard antithrombotic prophylaxis) at time of death. In these cases, the causes of death were massive pulmonary embolism, myocardial infarction, and not reported.

Progression to MF occurred in 37 (8%) patients, 8 of them under therapy with phlebotomies alone and the remaining after cytoreduction initiation. The probability of myelofibrosis at 10 and 20 years was 7% and 20%, respectively (Fig. 4). The probability of myelofibrotic transformation at 20 years was 14% and 30% in patients younger and older...
than 50 years, respectively \((p = 0.004)\). The \(JAK2V617F\) allele burden was available in 237 patients, and it was associated with a trend towards higher probability of myelofibrotic transformation (20-year probability: 4.7% and 33% in patients with low (< 50% VAF) and high (≥ 50% VAF) \(JAK2V617F\) allele burden, respectively, \(p = 0.08)\). On multivariate analysis, age > 50 years (HR: 2.5, 95%CI: 0.97–6.6, \(p = 0.06)\) and high \(JAK2V617F\) allele burden (HR: 2.06, 95%CI: 0.8–5.08, \(p = 0.12)\) at diagnosis were associated with a non-significant trend to higher risk of myelofibrosis.

Progression to AML was documented in 3 cases (1%). Age at time of acute transformation was 57, 64, and 65 years. Elapsed time from diagnosis to acute leukemia was 6 years in two cases and 9 years in one case. One of the patients had been treated with hydroxyurea for 3 years due to progressive leukocytosis and thrombocytosis under phlebotomies whereas the remaining two had not been exposed to cytoreductive therapy before AML.

**Thrombosis, bleeding, and second primary neoplasm under phlebotomies**

A total of 19 patients experienced a thrombotic event while on therapy with phlebotomies alone (12 arterial and 7 venous). With a 2239 person-years follow-up, the incidence rate of thrombosis was 0.8% per year and the estimated
The probability of arterial thrombosis at 10 years was 5.7%. Arterial hypertension was associated with a higher probability of arterial thrombosis in univariate analysis (11.7% versus 3.9% in patients with and without arterial hypertension, respectively, \( p = 0.02 \)). On multivariate analysis, arterial hypertension showed a tendency towards a higher risk of arterial thrombosis (HR: 2.98, 95%CI: 0.90–9.8, \( p = 0.07 \)) after adjustment for age and sex. The probability of venous thrombosis at 10 years was 3%, being higher in patients with high JAK2V617F allele burden (12% and 2.5% for patients with high and low allele burden, respectively, \( p = 0.058 \)). On multivariate analysis, JAK2 allele burden showed a non-significant trend to higher risk of venous thrombosis (HR 4.86, 95%CI: 0.9–26.3, \( p = 0.067 \)). Age at diagnosis, sex, smoking, diabetes, hypercholesterolemia, and hematological values at diagnosis, including leukocyte count, platelet count, and hemoglobin level, were not associated with the probability of total thrombosis, arterial thrombosis, or venous thrombosis during phlebotomy treatment.

Bleeding was reported in 12 (2.6%) patients, corresponding to major and minor bleeding in 4 and 8 patients, respectively. The rate of major bleeding was 0.18% per year. Second primary neoplasia was reported in 7 patients (0.3% per year) including 2 cases of colon carcinoma and one case each of renal carcinoma, bladder carcinoma, liposarcoma, melanoma, and angioma.

**Discussion**

There are few studies focusing on hematological and symptomatic control, incidence of complications, and need for cytoreduction in low-risk PV patients treated with phlebotomies. The present study included 453 low-risk patients from the Spanish Registry of PV who were initially treated only with phlebotomies. Notably, the median Hct value decreased from 54% at baseline to 45% at 12 months, but a sustained hematocrit < 45% was achieved only in third of patients. In addition, a significant proportion of patients persisted with PV-related symptoms, splenomegaly, leukocytosis, and/or thrombocytosis under phlebotomies, and in some of them, this led to indication for starting cytoreduction. Therefore, our data demonstrate that symptomatic and hematological control is not fully achieved in a proportion of patients treated with phlebotomies alone, providing the basis for initiating cytoreduction in low-risk PV patients. According to recent ELN recommendations (17), cytoreductive drugs should be considered in patients with persistent leukocytosis (> 15 × 10^9/l), extreme thrombocytosis (> 1500 × 10^9 platelets per l), or inadequate hematocrit control with phlebotomies (a need for at least six phlebotomies per year for at least 2 years in the maintenance phase). If we apply these criteria to our series, the proportion of low-risk patients treated with phlebotomies who might be candidates for cytoreduction due to persistent leukocytosis, extreme thrombocytosis, and inadequate Hct control would be 11%, 0%, and 19%, respectively.

Scherber et al. reported higher symptomatic burden in patients treated with phlebotomy alone than in those who received cytoreduction, highlighting the need for a correct symptom assessment in patients treated with phlebotomies [18]. In this regard, microvascular symptoms and pruritus were frequently reported in our series, but due to the retrospective study design, the severity of these symptoms was not assessed using the MPN-SAF or other standardized symptom scores, which prevents us from estimating what proportion of these patients might benefit from a trial of cytoreductive therapy.
The incidence of thrombotic events in our cohort of low-risk PV patients while receiving treatment with phlebotomies alone was 0.8% per year. The IWG-MRT [3], ECLAP [10], and CytoPV [11] studies reported rates of 2.62%, 4.4%, and 2.7% thrombotic events per year, respectively, but these studies included low- and high-risk PV patients. In fact, most of the events reported in patients treated with phlebotomies alone in the ECLAP study occurred in high-risk patients, with few thrombotic events reported in low-risk patients [10]. Overall, this low incidence of thrombosis is remarkable, considering that only 30–40% of patients in the ECLAP study and in our series had adequate hematocrit control over time [10]. These figures are in line with the Low-PV study in which the superiority of ropo-interferon alfa-2b over phlebotomies alone has been demonstrated, with hematocrit control in 66% of patients treated with phlebotomies under strict monthly hematological assessment [19]. Whether therapeutic intervention with cytoreduction could further reduce the incidence of thrombotic events in this low-risk population is unknown. Of note, a recent meta-analysis has reported a frequency of 0.5% thrombotic events per year in PV patients treated with interferon, a figure similar to that reported in the general population [20]. However, the low frequency of thrombotic events in this patient population makes difficult to show a benefit in primary prevention of thrombosis with conventional clinical trials.

In our series, the estimated median survival was longer than 30 years with more than 90% of patients being alive at 10 years from diagnosis. Only three deaths were reported under phlebotomies alone, two of them due to thrombotic complications reinforcing the need of adequate thrombotic prevention in this subset of patients. Relative survival analysis showed no reduction in expected survival when compared with the Spanish general population of same age and sex. This result should be interpreted with caution since the progression of the disease, especially to MF, could produce a reduction of survival in long-term survival not detected in our study. This is especially relevant for young patients and highlights the need of new agents with a disease-modifying effect for low-risk PV.

Although the present study constitutes a good representation of real practice in patients with low-risk PV managed with phlebotomies, several limitations should be considered when interpreting the results. The multicentric nature of the study is inevitably associated with differences in phlebotomy procedures, including the technique employed, the frequency of hematologic controls, or the total volume removed. It should be noted that no Hct evaluations were collected before month 6 precluding us to estimate the median elapsed time from diagnosis to Hct control under phlebotomies. In addition, hematological values during follow-up were not available in a significant proportion of patients, which precluded analysis of the association between hematocrit control and risk of thrombosis. Nevertheless, and despite its retrospective design, the present study constitutes a good representation of real-life clinical practice in a large series of low-risk PV patients with long follow-up.

We concluded that in low-risk PV patients managed with phlebotomies alone, the incidence of thrombosis and hemorrhage is low despite suboptimal hematological and symptomatic control. Progression to myelofibrosis constitutes an unmet need deserving the development of new treatment strategies.

Acknowledgements We are indebted to all members of GEMFIN participating in the Spanish Registry of Polycythemia Vera. We thank MFAR staff (Narcís Borrell and Eduard Cabrè) for their technical assistance.

Author contribution AT collected the data, interpreted the results, and wrote the paper. AAL designed the study, performed the statistical analysis, analyzed and interpreted the results, and wrote the paper. AP, MPE, MMM, PV, LF, MG, MG, RGD, MG, FF, VGG, AA, MTGC, BC, CM, RP, JMR, LG, IM, BB, JCHB, and CS collected the data, interpreted the results, and approved the final version.

Funding This work was supported by PI18/01472, PI18/00205, and PI21/00231 from the Instituto de Salud Carlos III (ISCIII), through the Plan Estatal de Investigación Científica y Técnica and de Innovación. GEMFIN received a grant from Novartis for the development of the Spanish Registry of Polycythemia Vera and for conducting the present project.

Declarations AAL participated in advisory board and received speaker and consulting fees from Novartis/AOP/Celgene. MPE participated in advisory board and received speaker fees from Novartis. MMM participated in advisory board and received speaker, consulting fees and support for attending meetings from Incyte/Novartis. FFM received research support from Incyte/CTI and speaker and consulting fees from Novartis/Incyte. VGG received grants from Novartis/BMS, consulting fees from Novartis/BMS, payment for lectures from Novartis/BMS, payment for expert testimony from Novartis/BMS, and support for attending meetings from Novartis/BMS and participated in advisory boards from Novartis/BMS. LF received consulting fees from SierraOnc/Novartis/BMS, payment for lectures from Novartis, and support for attending meetings from Novartis/Sanoﬁ. RGD received payment for lectures and expert testimony, and support for attending meetings and participated in advisory boards from Novartis/Jansen/AbbVie. RA received speaker honorarium from Astellas/Celgene/Novartis and participated in advisory board for Novartis/Incyte. BB participated and received speaker and consulting from Novartis. AT, AP, PV, AA, MG, MTGC, BC, CM, RP, JMR, LG, IM, JCHB, and CS have no conflict of interest to declare.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. IARC, LARC, editor.

2. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullen MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057–1069. https://doi.org/10.1038/s41375-018-0077-1

3. Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger A, Gisslinger B, Pieri L, Bertozzi I, Cassetti I, Pardanani A, Passamonti F, Vanucchi AM, Tefferi A (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124:3021–3023. https://doi.org/10.1182/blood-2014-07-591610

4. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109(6):2446–2452

5. Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L, Fernández-Rodríguez C, Gómez M, Lombardía L, Angona A, Ancocchea A, Senín A, Longarón R, Navarro B, Collado M, Besses C (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89(5):517–523. https://doi.org/10.1182/blood-2006-08-042515

6. Cerquozzi S, Barraco D, Laslo T, Finke C, Hans K, Ketterling TP, Pardanani A, Ganag T, Tefferi A (2017) Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 7(12):662. https://doi.org/10.1038/s41408-017-0035-6

7. Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 95(12):1599–1613

8. Pearson TC, Wetherley-Mein G (1978) Vascular occlusive episodes and venous hematocrit in primary proliferative polycythaemia. Lancet 2(8102):1219–1222. https://doi.org/10.1016/ajh.26008

9. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011) Treatment of polycythemia vera with hydroxyurea and piperobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29(29):3907–3913. https://doi.org/10.1200/jco.2011.36.0792

10. Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, Ghirardi A, Tognoni G (2017) A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol 92(11):1131–1136. https://doi.org/10.1002/ajh.24851

11. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Ellis E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Raperzzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadai A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T, CYTO-PV Collaborative Group (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33. https://doi.org/10.1056/nejmoa1208500

12. Enblom-Larsson A, Girodon F, Bak M, Hersdy D, Jooste V, Hasse1bch H, Johansson P, Andreasson B (2017) A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. Br J Haematol 177(5):800–805. https://doi.org/10.1111/bjh.14625

13. Gisslinger H, Klade C, Georgiev P, Krochmalczyzk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulycz P, Illes A, Pylypenko H, Sicveche L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbach HC, Krafovics R, Kiladjian JJ (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomized, non-inferiority phase 3 trial and its extension study. Lancet Haematol 7(3):e196–208. https://doi.org/10.1016/s2355-3026(19)30236-4

14. Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, Nosner C, Ritchie EK, Scandura JM, Silver RT (2021) Interferon-alpha for treating polycythaemia vera yields improved myelofibrosis-free and overall survival. Leukemia 25(9):2592–2601. https://doi.org/10.1038/s41375-021-01183-8

15. Kiladjian JJ, Klade C, Georgiev P, Krochmalczyzk D, Gercheva-Kyuchukova L, Egyed M, Dulycz P, Illes A, Pylypenko H, Sicveche L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbach HC, Krafovics R, Gisslinger H (2022) Long-term outcomes of polycythaemia vera patients treated with ropeginterferon alfa-2b. Leukemia 36:1408–1411. https://doi.org/10.1038/s41375-022-01528-x

16. Vannucchi A, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426–435. https://doi.org/10.1056/nejmoa1409002

17. Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Alvarez-Larran A, de Stefano V, Guglielmelli P, Palandrini F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T (2022) Appropriate management of polycythemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9:e301–e311. https://doi.org/10.1016/s2355-3026(22)00046-1

18. Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, Masciulli A, Scano M, Vannucchi AM, Mosa RA, Barbui T (2017) The potential role of hematocrit control on symptom burden among polycythaemia vera patients: insights from the CYTO-PV and MPN-SAP patient cohorts. Leuk Lymphoma 58(6):1481–1491. https://doi.org/10.1080/01453057.2016.1246733

19. Barbui T, Vannucchi AM, de Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandrini F, Benevolio G, Pane F, Ricco A, Carli G, Caramella M, Raperzzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Losocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A (2021) Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol 8(3):e175–e184. https://doi.org/10.1016/s2355-3026(20)30373-2

20. Bewersdors JF, Giri S, Wang R, Podolsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M (2021) Interferon alpha therapy in essential thrombocythemia and polycythaemia vera—systematic review and meta-analysis. Leukemia 35(6):1643–1660. https://doi.org/10.1038/s41375-020-01020-4

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Ana Triguero1 · Alexandra Pedraza1 · Manuel Pérez-Encinas2 · María Isabel Mata-Vázquez3 · Patricia Vélez4 · Laura Fox5 · Montse Gómez-Calafat6 · Regina García-Delgado7 · Mercedes Gasior8 · Francisca Ferrer-Marin9 · Valentín García-Gutiérrez10 · Anna Angona11 · María Teresa Gómez-Casares12 · Beatriz Cuevas13 · Clara Martínez14 · Raúl Pérez15 · José María Raya16 · Lucía Guerrero17 · Ilda Murillo18 · Beatriz Bellosillo4 · Juan Carlos Hernández-Boluda6 · Cristina Sanz1 · Alberto Álvarez-Larrán1 on behalf of On behalf of the MPN Spanish Group (GEMFIN)

1 Hospital Clinic de Barcelona, Barcelona, Spain
2 Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
3 Hospital Costa del Sol, Marbella, Spain
4 Hospital del Mar, Barcelona, Spain
5 Hospital Universitario Vall d’Hebron, Hematología Experimental, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
6 Hospital Clínico Universitario de Valencia, Valencia, Spain
7 Hospital Universitario Virgen de La Victoria, Málaga, Spain
8 Hospital Universitario La Paz, Madrid, Spain
9 Hospital Universitario Morales-Meseguer, CIBERER-UCAM, Murcia, Spain
10 Hospital Universitario Ramón Y Cajal (IRYCS), Madrid, Spain
11 ICO Girona-Hospital Josep Trueta, Girona, Spain
12 Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
13 Hospital Universitario de Burgos, Burgos, Spain
14 Hospital de La Santa Creu I Sant Pau, Barcelona, Spain
15 Hospital Universitario Clínico Virgen de La Arrixaca, Murcia, Spain
16 Hospital Universitario de Canarias, Tenerife, Spain
17 Hospital Rio Carrión, Palencia, Spain
18 Hospital General San Jorge, Huesca, Spain